Your session is about to expire
← Back to Search
SEA-BCMA for Multiple Myeloma
Study Summary
This trial is studying SEA-BCMA to see if it's an effective treatment for MM and what side effects may occur.
- Multiple Myeloma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had bad reactions to corticosteroids in the past.You are able to perform everyday activities without any problems or with only a little restriction due to your cancer.Your blood, kidney, and liver are working well.You have a severe, uncontrolled infection.You must have finished any previous cancer treatments at least 4 weeks before starting the study, or 2 weeks if the cancer is getting worse. If you had CAR-T-cell therapy, it must have been finished 8 weeks before starting the study.You have already been treated with specific types of medications.You have been treated with a specific therapy targeting BCMA in the past.You have had another type of cancer in the past 3 years.You have ongoing brain or spinal cord disease related to your cancer.You have unmanaged mental health issues.You have a confirmed diagnosis of multiple myeloma through tissue sample analysis.You must have multiple myeloma that has come back after treatment or is not responding to treatment.You have a certain level of proteins in your blood or urine that can be measured to show the disease.
- Group 1: Parts A and B: SEA-BCMA Monotherapy
- Group 2: Part C: SEA-BCMA + Dexamethasone Combination Therapy
- Group 3: Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What prior investigations have been conducted regarding SEA-BCMA?
"Presently, 575 medical studies are being conducted in regards to SEA-BCMA. 145 of those active clinical trials have entered Phase 3, and the majority are located in Joliet, Illinois; although there exists 19007 other sites running similar research for this treatment."
What adverse effects has SEA-BCMA been linked to in individuals?
"Considering there is limited data to support the safety and efficacy of SEA-BCMA, our team has assigned it a score of 1 on a scale from 1 to 3."
What condition is SEA-BCMA primarily prescribed to alleviate?
"SEA-BCMA is primarily prescribed to treat ophthalmia, sympathetic. However, it can also be an effective way of managing the symptoms associated with eye branch retinal vein occlusion and macular edema."
How many participants are invited to join this research?
"According to the research requirements, 131 suitable participants must be recruited for the trial. Seagen Inc., who is sponsoring this project, will manage it from multiple hubs; including Weill Cornell Medicine in New york and Willamette Valley Cancer Institute/Oncology Assc of Oregon in Eugene."
Are there any recruitment slots available for this research endeavor?
"The clinicaltrial.gov website confirms that this investigation is actively seeking participants, having first been posted November 1st 2018 and most recently updated on August 24th 2022."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger